Phase I study of YM155, selective survivin suppressant in combination with elrotnib in patients with EGFR-mutant advanced non-small cell lung cancer.

Toshio Shimizu,Kazuto Nishio,Kazuko Sakai,Hidetoshi Hayashi,Kunio Okamoto,Masayuki Takeda,Tsutomu Iwasa,Kaoru Tanaka,Koji Aoyama,Maiko Morishita,Kazuhiko Nakagawa

Phase I study of YM155, selective survivin suppressant in combination with elrotnib in patients with EGFR-mutant advanced non-small cell lung cancer.

2016

Toshio Shimizu
Kazuto Nishio
Kazuko Sakai
Hidetoshi Hayashi
Kunio Okamoto
Masayuki Takeda
Tsutomu Iwasa
Kaoru Tanaka
Koji Aoyama
Maiko Morishita
Kazuhiko Nakagawa

e20585Background: Based on the mechanism of action and preclinical evidence of overcoming EGFR-TKI resistance in EGFR mutant non-small cell lung cancer (NSCLC) cells by targeting survivin, a member...

Keywords:

Survivin
Cell
Lung cancer
Mutant
Pathology
Cancer research
Medicine
in patient
non small cell
phase i study
Mechanism of action

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations